GSK
NEWS
Billionaire Sir Richard Branson believes in healthcare. This week he put more of his money where his mouth is by using his SPAC to take consumer DNA testing company 23andMe public in a massive deal.
It was a busy week for clinical trial updates. Here’s a look.
Less than one week after posting a positive first-look at Phase III vaccine data, Maryland-based Novavax began the rolling review process for authorization of NVX-CoV2373 in the United Kingdom, Canada and the United States.
Treatments for HIV are poised for another breakthrough. Researchers at Washington University in St. Louis (WUSTL) have discovered a way to eradicate dormant HIV virus within the cells, before it becomes active.
The collaboration is valued at €150 million (approximately $180 million). The two companies already have a history of working together.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
China’s Clover Biopharmaceuticals is spurning GlaxoSmithKline’s adjuvant vaccine technology in favor of one created by California-based Dynavax Technologies.
The pharmaceutical industry continues to demonstrate its willingness to team up in the ongoing combat against the global COVID-19 pandemic.
It was a busy week for clinical trial news. Read on for more information.
JOBS
IN THE PRESS